Aspen Neuroscience

[Not Yet Scheduled]
Parkinson disease (PD) is the second most common neurodegenerative disease, affecting more than 10 million people worldwide and costing more than $50 billion annually. PD is caused by progressive degeneration of the dopamine neurons in a part of the brain called the substantia nigra. There is currently no available therapy that can halt the degeneration or reverse the symptoms. Aspen Neuroscience’s goal is to reverse the disease symptoms by providing the world’s first autologous induced pluripotent stem cell (iPSC)-derived dopamine neuron replacement therapy for PD. Our extensive experience in stem cell biology and genomics enables us to develop a cost-effective patient-specific therapy in which a person’s own cells are used to replace the dying dopamine neurons. Autologous therapy will not require immunosuppression and its resulting health problems. Aspen was founded in 2018 and is venture capital-funded.
Company Type:
Privately Funded Company
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
ANPD001; autologous dopamine neuron therapy for Parkinson disease
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
Aspen Neuroscience